Shares of Sharon Bio Medicine surged almost 6% as the company declared that its Taloja plant has been approved by the European drug agency-European Directorate for the Quality of Medicines & Healthcare (EDQM). The company said the move will enhance its sales in Europe and other countries.
Shares of Sharon Bio Medicine are currently trading at Rs 47.50-a-piece up 4.6% or on the Bombay Stock Exchange (BSE). A total of 7,64,838 shares changed hands on both BSE and NSE as compared to its 30-day average trading volume of 6,44,361. The share touched a high of Rs 50.65 and a low of Rs 45.30 during the day.
On Monday, the company, in an exchange said," Sharon Bio-Medicine Ltd has informed BSE that the Company's Active Pharma Ingredient manufacturing Plant at Plot No. L-6, MIDC, Taloja, near Navi Mumbai Dist. Raigad, Maharashtra has been approved by European Directorate for the Quality of Medicines & Healthcare (EDQM) Council of Europe for complying with the certificate of suitability, as well as the implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal Product in the European Union, the Company operates in accordance with the requirements of the Resolution AP-CSP (07) 1. This will further enhance the sales to Europe and other countries in near future."
Shares of Sharon Bio Medicine are currently trading at Rs 47.50-a-piece up 4.6% or on the Bombay Stock Exchange (BSE). A total of 7,64,838 shares changed hands on both BSE and NSE as compared to its 30-day average trading volume of 6,44,361. The share touched a high of Rs 50.65 and a low of Rs 45.30 during the day.
On Monday, the company, in an exchange said," Sharon Bio-Medicine Ltd has informed BSE that the Company's Active Pharma Ingredient manufacturing Plant at Plot No. L-6, MIDC, Taloja, near Navi Mumbai Dist. Raigad, Maharashtra has been approved by European Directorate for the Quality of Medicines & Healthcare (EDQM) Council of Europe for complying with the certificate of suitability, as well as the implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal Product in the European Union, the Company operates in accordance with the requirements of the Resolution AP-CSP (07) 1. This will further enhance the sales to Europe and other countries in near future."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%